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a,-Antitrypsin has been isolated from individuals with inherited genetic variants M,, X and 2. A fragmentation and 
peptide mapping system is described which together with amino acid and sequence analyses revealed the substitutions 
in M, at 376 of Glu to Asp, in X at 204 of Glu to Lys and in the physiologically innocent Z a mutation at 213 of Val 
to Ala. The latter represents a second amino acid substitution in the Z protein. 
a-,-Antitrypsin; Genetic variant; Amino acid sequence; Peptide mapping 
1. INTRODUCTION 
The major human, extracellular serine protease 
inhibitor (Pi), cui-antitrypsin (W-AT), has at- 
tracted biomedical interest owing to its genetic 
polymorphism [ 11, its unusually pronounced 
microheterogeneity [2], and because some of the 
genetic variants are accompanied by a slight to 
pronounced decrease in plasma W-AT content. A 
few of these mutations predispose for development 
of lung diseases [3], and one of them for liver 
diseases [4]. 
The complete amino acid sequence (394 
residues) of baboon al-AT was deduced from 
cDNA studies [5], and established in humans for 
the most common PiM variant after direct amino 
acid sequence analysis [6]. A 24-residues long 
prepeptide has also been identified [7]. 
More than 50 alleles contribute to the genetic 
polymorphism of W-AT, which is preferably deter- 
mined by means of isoelectric focusing of plasma 
after reduction of its mixed disulphides [S]. Single 
amino acid substitutions have been established 
where Glu in positions 264 and 342 has been 
replaced by Val and Lys, respectively, in the PiS 
and PiZ variants, both of which are accompanied 
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by decreased concentration of al-AT in plasma 
[9,10]. Recent observations indicate that the 
altered plasma homeostasis for the PiZ variant is 
attributable to its postribosomal metabolism [ 111. 
The entire nucleotide sequence of the Z gene has 
recently been completed [12]. In addition to the 
342 Glu-Lys substitution, another point mutation 
(GIG to GCG) was found which predicts an amino 
acid substitution, at 213 of Val to Ala, without any 
apparent effect on the function or metabolism of 
the Z protein. 
The reactive site of cu-antitrypsin responsible for 
its inhibition of serine proteases, primarily 
elastase, is centered on the methionine residue 358, 
located 37 residues from the C-terminus of the 
molecule [ 131. A mutation of this Met to Arg con- 
verts al-AT from an anti-elastase to an anti- 
thrombin, resulting in a bleeding tendency [14]. An 
LY,-AT mutant (Christchurch) with Lys-363 instead 
of Glu-363 close to the active center has a normal 
protease inhibitory activity [ 151. 
A peptide mapping system for al-AT is reported 
here, and its usefulness is exemplified by the iden- 
tification of the amino acid substitutions of the 
PiMj, PiX and PiZ proteins. 
2. MATERIALS AND METHODS 
2.1. Material 
Citrated blood plasma from subjects of various Pi types was 
obtained from the hospital blood center. 
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2.2. Reagents 2.6. Amino acid and sequence determination 
Most reagents and trifluoroacetic acid (Arista@ grade) were 
reagents from BDH. Acetonitrile (HPLC grade) was obtained 
from Blackford, Wells Limited, England. Pharmalytes 4.2-4.9 
were from Pharmacia (Uppsala, Sweden). Lysylendopeptidase 
was obtained from Wako (Osaka, Japan). Chemicals for se- 
quence determination were from Applied Biosystems (Foster 
City, CA). 
2.3. Equipment 
Amino acid analyses of collected fraction peaks were per- 
formed after hydrolysis in 6 M HCl at 110°C for 24 h and using 
a Beckman 6300 amino acid analyzer. Automated Edman 
degradation was performed on a gas-phase sequencer (model 
470 A) from Applied Biosystems equipped with an on-line 
detection system, Applied Biosystems model 120 A PTH- 
analyzer. The apparatuses were operated according to the 
manufacturer. 
A Pharmacia FPLC system, including two P-500 pumps, a li- 
quid chromatographic controller (LCC-SOO), a 214 nm UV- 
detector with a HR-10 mm cell and a fraction collector with a 
RST-100 valve was used for all chromatographic separations. 
3. RESULTS 
3.1. The peptide mapping system 
2.4. Purification of CYI-AT 
The genetic variants of @l-AT were determined by isoelectric 
focusing, using a Pharmalyte 4.2-4.9 gradient in a 
polyacrylamide gel [8]. cut-AT from individuals were purified 
with a SH-SS interchange chromatography system with minor 
modifications [16]. After an initial precipitation of low density 
lipoproteins (20 ~1 10% dextran sulphate, 100 11 of 1 M CaClz 
per ml plasma), the supernatant was slightly reduced with fi- 
mercaptoethanol, at a final concentration of 0.02 M, for 0.5 h. 
Salt and reducing agent from 50 ml plasma was separated from 
proteins by gel filtration on a Sephadex G-25 column (5 x 
30 cm with 0.05 M Tris buffer, pH 8). The plasma proteins with 
reactive SH-groups &-AT, albumin, prealbumin) were retain- 
ed in a column with activated thiol-Sepharose at pH 8. After 
washing and release of (YI-AT by reduction, contaminating 
albumin, prealbumin and some other contaminants were 
separated by passage through Blue Sepharose and anti- 
prealbumin Sepharose columns. The three columns had a 
volume of 50 ml each. After concentration of the proteins to 
some 3 ml, a final gel filtration on AcA-54 (1.6 x 80 cm in 
0.05 M ammonium bicarbonate) gave 99% pure (UI-AT at a 
yield of about 50%. 
2.5. The peptide mapping system 
The purified cul-AT was reduced and carboxymethylated. 
CNBr degradation (300 moles CNBr per mol Met) was perform- 
ed in 70% (w/v) formic acid, at room temperature for 24 h for 
batches of 5 mg LYI-AT. 
After the CNBr degradation the lyophilized 
material had to be dissolved in guanidine-HCl and 
the column run in 30% acetonitrile to deaggregate 
the most hydrophobic peptides. Three larger 
(I-III) CNBr fragments were separated from a 
group of smaller ones by HPLC gel filtration on 
prepacked Superose 12 (fig.1). An increase in 
capacity from 1 to 5 mg material has recently been 
made possible by using a 1.6 x 80 cm Superose 12 
column. The amino acid composition of the in- 
dividual RP-HPLC peaks of lysylpeptides from 
fragments I-III was matched by the known se- 
quence data. Position 220-221 represents a Met- 
Met sequence ending the largest CNBr fragment 
(II). The lysylendopeptidase gave more reproduci- 
ble peptides than TPCK-trypsin, although some 
peptides became larger. The smaller CNBr 
fragments IV-IX were satisfactorily separated on 
the RP-HPLC system (fig.3). Met-358 appeared as 
homoserine in the C-terminal fragment VI 
(352-358) and as unreacted Met in the larger com- 
bined fragment VI-VII (352-374). It was evident 
After lyophilization, the material was dissolved in 0.2 ml of 
6 M guanidine-HCl and separated on two Superose 12 columns 
(Pharmacia) in tandem, equilibrated with 0.05 M ammonium 
bicarbonate in 30% acetonitrile. The flow rate was 0.8 ml/min 
and fractions were collected as marked on fig. 1 and lyophilized. 
Each of the three larger fragments (I-III) was dissolved in 
0.1 M ammonium bicarbonate and digested with lysylendopep- 
tidase at an enzyme to substrate ratio of 1: 100 (w/w) for 3 h. 
The reaction was terminated by the addition of one drop of 6 M 
HCl. The lysylpeptides and the smaller CNBr fragments IV-IX 
were subjected to reversed-phase HPLC. 
Peptides (0.25-0.5 mg) or CNBr fragments were directly in- 
jected into a Pharmacia HR 5/5 Pep RPC prepacked column 
(Cz/Cls, 5 ym particle size, 300 A pore size). Solvent A was 
0.1% trifluoroacetic acid (TFA) in water and solvent B was 
0.1% TFA in acetonitrile/water (80: 20). Elution was perform- 
ed with an 80 min linear gradient from 0 to 60% B at a flow rate 
of 1 .O ml/min. The level sensor and delay functions in the frac- 
tion collector facilitated the collection of all major peaks. 
Fig. 1. Gel filtration pattern of cyanogen bromide fragments of 
carboxymethylated cyl-antitrypsin. Two Superose 12 columns in 
tandem were eluted with 0.05 M NH4HCO3 in 30% 
acetonitrile. Parts of the effluent were collected as indicated by 
bars. Fraction collection was started after 40 min. 
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Fig.2. Separation of lysylpeptides from the largest CNBr 
fragment II on a Cz/Cts (Pep RPC 5/5) column. Peptide 14 
(residues 202-217) represents the normal M position. The Z 
position reflects the 213 substitution (Val-Ala) in the Z protein. 
The X marks the position of peptide 14, devoid of the three first 
amino acids depending on a 204 Glu-Lys substitution in the X- 
protein. 
from this chromatographic profile that Met-358 of 
the reactive site must have been partially oxidized 
to methionine sulphoxide, which does not react 
with CNBr. 
3.2. Peptide mapping of the genetic CYI-AT 
variants PiM3, PiX and PiZ 
Both the HPLC gel filtration on Superose 12 
and all RP-HPLC on C2/Cie columns gave normal 
patterns of CNBr fragments and lysylpeptides 
from the M3 protein. However, amino acid 
analysis of one of the purified smaller CNBr 
fragments gave evidence for a Glu-Asp replace- 
ment in fragment VIII. Sequence analysis of this 
fragment proved a substitution at 376 of Glu to 
Asp in M3 protein. When separating the lysylpep- 
tides from the CNBr fragment II of the X protein, 
Fig.3. RP-HPLC of all smaller CNBr fragments IV-IX on 
Cz/Cts column. The actual residues are given at the top of the 
peaks. The methionine (358) in the active center is only partially 
cleaved by CNBr. Thus a combined Vl+Vll fragment is 
obtained besides the individual fragments VI and VII. 
an aberrant peak was obtained. The sequence of 
peptide 14 was found to be: Asp-Thr-Glu-Glu-Glu- 
Asp-Phe-His-Val-Asp-Glu-Val-Thr-Thr-Val-Lys. 
The first three amino acids in the aberrant peptide 
were missing as indicated both by the amino acid 
content and the sequence analysis. A new tripep- 
tide, Asp-Thr-Lys, was found in the front peak in- 
dicating a Glu-Lys substitution for 204. 
Z protein was run in the same peptide mapping 
system. The same peptide 14 now appeared to be 
less hydrophobic (see fig.2). Sequence analysis in- 
dicated a Val-Ala substitution for 213. 
4. DISCUSSION 
On electrofocusing, each phenotype of al-AT 
separates into five subfractions, two major, 4 and 
6, and three minor, 2, 7 and 8. Subfractions 7 and 
8 have the same variants of carbohydrate structure 
as the major subfractions 4 and 6, but have lost 
their first N-terminal amino acids: Glu-Asp-Pro- 
Glu-Gly [2]. This loss of three acid amino acids ex- 
plains their higher pl values. The major subfrac- 
tions 4 and 6 of the PiX protein which we have 
investigated have exactly the same pZ values as the 
PiM 7 and 8, respectively. This is in good agree- 
ment with the finding of Glu-Lys substitution at 
204 of PiX, adding two charge units. The same 
substitution pair was found already in 1976 in the 
Z protein [lo]. Also, PiX and PiZ have similar 
positions on agarose electrophoresis, but show a 
small difference on electrofocusing. The second 
substitution in the Z protein at 213 (Val-Ala) as 
deduced from nucleotide sequence of the coding 
region of the PiZ gene [12], was verified with our 
peptide mapping system. In our earlier complete 
sequence of the M-protein we had obtained a clear 
Val in position 213 [6]. However, the cDNA work 
of Woo and co-workers [17] showed Ala, sug- 
gesting a polymorphism. This can now be explain- 
ed by the findings that also 23% of the Ml 
haplotypes has the 213 Val-Ala substitution found 
in all Z proteins studied [12]. This 213 mutation is 
electrophoretically silent and located on the sur- 
face of the molecule. 
The replacement of acid starch gel elec- 
trophoresis with electrofocusing for genetic Pi typ- 
ing has revealed at least four additional M 
subtypes M2-5. Unfortunately they have been 
named chronologically as they were detected, and 
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not with regard to differences in pl [l]. The PiM3 
occurs in 15% of the Scandinavian population. In 
contrast to the very small difference in pl values 
between Mi and M3 (less than 0.005 pH units), 
they separate on conventional agarose gel elec- 
trophoresis in barbital buffer at pH 8.6. MS pro- 
tein migrates slightly faster than Mi protein. The 
side chain of Glu-376 normally creates a hydrogen 
bond to His-350. The substituted amino acid Asp 
has a side-chain too short to establish this 
hydrogen bond at alkaline pH. Among five dif- 
ferent DNA sequences published, one group [18] 
found a difference in one nucleotide sequence 
causing a single amino acid substitution in position 
376, Glu-Asp. It is thus evident that this human 
liver cDNA library was isolated from a 
homozygous PiM3 subtype. 
Acknowledgements: The skillful technical assistance of Miss 
Maria Johansson and Miss lngrid Dahlqvist is greatly ap- 
preciated. This research was supported by grants from the 
Swedish Medical Research Council (project B-86-01X- 
0581-19C) and from the Faculty of Medicine, University of 
Lund, Sweden. 
REFERENCES 
[1] Fagerhol, M.K. and Cox, D.W. (1981) Adv. Human 
Genet. 11, l-62. 
[2] Jeppsson, J.-O., Lilja, H. and Johansson, M. (1985) J. 
Chromatogr. 327, 173-177. 
[31 
(41 
151 
161 
171 
PI 
191 
UOI 
[Ill 
WI 
1131 
1141 
1151 
1161 
iI71 
H81 
Eriksson, S. (1964) Acta Med. Stand. 175, 197-202. 
Sharp, H.L., Bridges, R.A. and Krivit, W. (1969) J. Lab. 
Clin. Med. 73, 934-939. 
Kurachi, K., Chandra, T., Friezner, S.J., White, T.T., 
Woo, S.L.C. and Davie, E.W. (1981) Proc. Natl. Acad. 
Sci. USA 78, 6826-6830. 
Carrel, R.W., Jeppsson, J.-O., Laurell, C.-B., Brennan, 
S.O., Owen, M.C., Vaughan, L. and Boswell, D.R. 
(1982) Nature 298, 329-334. 
Carlson, J. and Stenflo, J. (1982) J. Biol. Chem. 257, 
12987-12994. 
Jeppsson, J.-O. and Franzen, B. (1982) Clin. Chem. 28, 
219-225. 
Owen, M.C., Carrell, R.W. and Brennan, S.O. (1976) 
Biochim. Biophys. Acta 453, 257-260. 
Jeppsson, J.-O. (1976) FEBS Lett. 65, 195-197. 
Bathurst, l.c., Errington, D.M., Foreman, R.C., Judah, 
J.D. and Carrell, R.W. (1985) FEBS Lett. 183, 304-308. 
Nukiwa, J., Brantly, M., Ogushi, F., Fells, G., Satoh, K., 
Stier, L., Courtaney, M. and Crystal, G.R. (1987) 
Biochemistry 26, 5259-5267. 
Carrel], R.W., Jeppsson, J.-O., Vaughan, S.O., Brennan, 
S.O., Owen, M.C. and Boswell, D.R. (1981) FEBS Lett. 
135, 301-305. 
Owen, M.C., Brennan, S.O., Lewis, J.H. and Carrel], 
R.W. (1983) N. Engl. J. Med. 309, 694-698. 
Brennan, S.O. and Carrell, R.W. (1986) Biochim. Bio- 
phys. Acta 873, 13-16. 
Laurel], C.-B., Dahlqvist, 1. and Persson, U. (1983) J. 
Chromatogr. 278, 53-61. 
Leicht, M., Long, G.L., Chandia, T., Kurachi, K., Kidd, 
V.J., Mace, M. jr, Davie, E.W. and Woo, S.L.C. (1982) 
Nature 297, 655-659. 
Rogers, J., Kalsheker, N., Wallis, S., Speer, A., Coutelle, 
C.H. and Humphries, S.E. (1983) Biochem. Biophys. 
Res. Commun. 116, 375-382. 
330 
